RSV Seasonal Vaccine Introduction and Growth Strategy
Upcoming pipeline catalysts: 2023 and 2024
Regulatory
submission &
acceptance
Regulatory
decision
Phase II
Late stage
readouts
Phase III
H2 2023
H12024
H2 2024
Infectious diseases
HIV (VIIV)
Respiratory/Immunology
Oncology
Opportunity driven
Jemperli - RUBY, DMMR/MSI-H IL endometrial cancer
momelotinib - MOMENTUM, myelofibrosis
cabotegravir (long-acting) pre-exposure
Vocabria HIV treatment
RSV older adults vaccine candidate - ā„60 YoA
US
EU
CN
JP
55
US
Jemperli - RUBY, DMMR/MSI-H 1L endometrial cancer
momelotinib - MOMENTUM, myelofibrosis
EU
Nucala severe asthma
CN
EU, JP
ā
Nucala CRSWNP
gepotidacin - EAGLE-2/3, UUTI
Arexvy 50-59 YOA
JP
US, EU
US, EU, JP
Nucala CRSWNP
momelotinib - MOMENTUM, myelofibrosis
gepotidacin - EAGLE-2/3, UUTI
Arexvy -50-59 YoA
CN, JP
JP
US, EU
US, EU, JP
Blenrep - DREAMM-7, 2L+ multiple myeloma
Blenrep - DREAMM-8, 2L+ multiple myeloma
Jemperli - RUBY part 2, IL endometrial cancer
MenABCWY vaccine 1st Gen
US, EU
Nucala MATINEE, COPD
US, EU
gepotidacin- - EAGLE-1, GC
US, EU
US, EU
-
Blenrep DREAMM-7, 2L+ multiple myeloma
Blenrep - DREAMM-8, 2L+ multiple myeloma
Arexvy 50-59 YoA
Jemperli - RUBY part 2, IL endometrial cancer
Zejula - FIRST, IL maintenance ovarian cancer
gepotidacin - EAGLE-1, GC
linerixibat - GLISTEN, cholestatic pruritus in PBC
depemokimab - SWIFT-1/2, asthma
depemokimab - ANCHOR-1/2, CRSWNP
Nucala - MATINEE, COPD
cobolimab - COSTAR, 2L NSCLC
Zejula' - ZEAL, IL maintenance NSCLC
GSK
1. Tesaro asset
bepirovirsen B-TOGETHER, HBV
MenABCWY vaccine 2nd Gen
36
36
US
US
553View entire presentation